Mol Pharmacol 2021 01;99(1):49-59
Biogen, Cambridge, Massachusetts (C.A.H., H.N.); Charles River Laboratories Cleveland, Inc., Cleveland, Ohio (Y.K.); Neuroservice, Aix-en-Provence, France (A.S., A.B., B.B.); and Department of Comparative Medicine, Yale University, New Haven, Connecticut (M.H.).
Voltage-gated sodium channels (Navs) are promising targets for analgesic and antiepileptic therapies. Although specificity between Nav subtypes may be desirable to target specific neural types, such as nociceptors in pain, many broadly acting Nav inhibitors are clinically beneficial in neuropathic pain and epilepsy. Here, we present the first systematic characterization of vixotrigine, a Nav blocker. Read More